Systemic reactions to immunotherapy: influence of composition and manufacturer
| Autor: | M. T. Audicana, Eduardo Fernández, M. Etxenagusia, Daniel Muñoz, Gabriel Gastaminza, Jaime Algorta |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Allergy business.industry Incidence (epidemiology) medicine.medical_treatment Immunology Allergen extract medicine.disease_cause medicine.disease Allergen Internal medicine medicine Immunology and Allergy business Adverse effect Anaphylaxis Desensitization (medicine) Asthma |
| Zdroj: | Clinical & Experimental Allergy. 33:470-474 |
| ISSN: | 0954-7894 |
| DOI: | 10.1046/j.1365-2222.2003.01644.x |
| Popis: | Summary Background Although immunotherapy clearly demonstrated the benefit of reducing allergic symptoms, it has the drawback of adverse events, mainly systemic reactions that could be very inconvenient for patients and even life-threatening. Objective The aim of the present study was to assess the incidence of systemic reactions to immunotherapy in a large number of patients, and its potential relationship with the characteristics of therapy, such as allergen composition or manufacturing laboratory. Methods This study analysed the administration of specific immunotherapy during a period of 5 years, involving 1212 patients affected by respiratory hypersensitivity or hymenoptera venom anaphylaxis. Commercial extracts were supplied by five different laboratories. All the patients were attended at an out-clinic immunotherapy unit by the same experienced staff. Immunotherapy was given following a conventional schedule, modified according the usual recommendations. Results A total of 250 adverse reactions have been recorded, resulting in a frequency of 0.84% over the total number of injections. Seventy-nine of them (32%) were systemic reactions (0.27% SR/injection). The 79 systemic reactions were observed in 60 patients (5% of the patients). The frequency of systemic reactions was significantly lower (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|